9 results about "Immunologic Diagnosis" patented technology

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-terminal deoxynucleotidyl transferase (TdT) antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody disclosed by the invention can specifically recognize TdT protein naturally expressed in cells and tissues, has the advantages of high specificity, high affinity, high sensitivity and the like when being used for immunoblotting, immunohistochemistry and other immunodetection systems, is beneficial to reducing false positive and false negative rates in pathological diagnosis, improves the accuracy of immunodiagnosis, and has a good application prospect. The method has wide application potential in the field of immunological detection of living biological samples. In addition, the antibody disclosed by the invention has cross-species reaction characteristics on homologous TdT proteins of human, mice and rats, so that the application scene of the antibody is greatly expanded.

The invention discloses an application of TMEM106A as a target spot in preparation of a diagnostic kit and a targeted therapeutic drug. Relates to the technical field of immunodiagnosis. Specific applications are provided. The invention discloses a key effect of TMEM106A in podocyte injury related to preeclampsia. TMEM106A is significantly down-regulated in urine of a PE patient, is closely related to podocyte injury and inflammatory response, and can be used as an early noninvasive diagnostic marker; meanwhile, the targeted podocyte up-regulation TMEM106A has remarkable anti-inflammatory and kidney protection effects, and a theoretical basis and practical feasibility are provided for targeted therapy of PE-related podocyte injury. The invention provides a new way for early precise diagnosis and intervention strategy of PE, and has wide clinical application prospect.

The application provides a Bola type surfactant-based blocking agent, which can be used for modifying various object surface materials, especially the surface of a carrier material for immune diagnosis, so that the non-specific adsorption of the carrier material is reduced, and the sensitivity and signal-to-noise ratio of a reagent are improved. Compared with traditional blocking agents, the Bola type surfactant-based blocking agent provided by the application not only has the excellent characteristics of traditional surfactant blocking agents, but also has increased repulsion to non-specific molecules and more compact blocking due to the rigid hairpin structure after combination.

The present disclosure provides a fusion protein, a conjugate containing the same, a kit and use, belonging to the technical field of immunodiagnosis. The fusion protein of the present disclosure comprises a protein tag and a protein part, the fusion protein containing the protein tag has improved activity or specificity, and the fusion protein is used for immunodetection, which can improve the sensitivity or specificity of immunodetection.

The present invention relates to an immune device for determining the presence or absence of pregnancy or abnormal pregnancy, and more specifically, to an immune device capable of recognizing both intact hCG and βcf hCG. R This immunological device contains a multi-linked anti-hCG monoclonal antibody, and can separately detect intact hCG and βcf hCG contained in the sample, including two detection lines and a control line.By quantifying the ratio of the color intensity of βcf hCG to the color intensity of intact hCG and βcf hCG (the distribution ratio of βcf hCG), it can accurately and quickly determine the number of weeks of pregnancy, normal pregnancy, ectopic pregnancy, and abnormal pregnancy including blighted oocytes.

The invention belongs to the technical field of in-vitro diagnosis, and discloses a preparation method of a high-sensitivity chemiluminescent reagent for in-vitro diagnosis, which is characterized in that an electron donating group (methoxyl) and a steric hindrance group (tert-butyl) are introduced on the basis of a traditional luminol structure, so that the electron density and stability of a molecular conjugated system are remarkably enhanced, and the chemiluminescent reagent has high sensitivity. The light-emitting quantum efficiency and the oxidation resistance of the substrate are improved. Meanwhile, Co < 2 + > or Ni < 2 + > is adopted as a transition metal catalytic center and cooperates with a phenol enhancer to construct a two-channel free radical enhancement system, the luminol oxidation luminescence process is effectively accelerated, and the luminescence duration is prolonged. The preparation method of the reagent comprises the following steps: synthesizing a luminol derivative, preparing a metal catalyst solution and a phenol enhancer solution, and mixing according to an optimized ratio. The luminescent system shows high signal-to-noise ratio and excellent repeatability in low-concentration biomarker detection, the lowest detection limit is less than 1pg / mL, and the luminescent system is suitable for high-sensitivity in-vitro immunodiagnosis analysis.

The invention relates to the technical field of antibodies, in particular to an OXA-23 enzyme monoclonal antibody and application thereof. When the OXA-23 enzyme monoclonal antibody is used for immunodetection, the OXA-23 enzyme monoclonal antibody has high sensitivity, high affinity to antigens and good specificity, is suitable for being used as an immunodiagnosis reagent, can be used for in-vitro diagnosis of OXA-23 enzyme, and has a wide application prospect.

The application discloses a CBA method reagent for detecting GFAP antibody by fusing expression of GFAP alpha and GFAP epsilon and a detection method, and belongs to the technical field of neuroimmunological diagnosis. The reagent comprises a host cell which is recombined to express a fusion protein. The fusion protein comprises the following functional domains in sequence: a secretion signal peptide, a GFAP alpha partial sequence, a GFAP epsilon partial sequence, a transmembrane sequence and a fluorescent label. The core of the application is that the fusion cell is constructed by using the partial sequences of GFAP alpha and GFAP epsilon, and the co-expression is realized in the host cell by using the co-transfection technology. The sensitivity and the specificity of the detection of the CFAP antibody in the CBA method (cellular immunofluorescence method) can be significantly improved.

The present invention relates to a composition and imaging technology for evaluating the immune response of T cells, and in particular, to the technological field of T cell activation analysis and infectious disease diagnosis using lens-free shadow imaging. According to the present invention, activation of T cells can be effectively induced through a T cell activation composition composed of a specific component combination (PHA, PMA, ionomycin, etc.), and T cell activation-specific image parameters (MMD_SD etc.) can be acquired from the activated T cells through lens-free shadow imaging technology. Moreover, since a T cell activity analysis device and method using these parameters exhibit significant performance in diagnosing the presence or absence of latent tuberculosis infection, the present invention has the effect of providing a biological composition that can be used for T cell functional analysis, creating a non-labeling immunodiagnostic platform, and presenting a novel analytical index for LTBI diagnosis.